Altius Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 08-12-2024
- Paid Up Capital ₹ 0.55 M
as on 08-12-2024
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.30 M
as on 08-12-2024
- Revenue 40.19%
(FY 2022)
- Profit 66.42%
(FY 2022)
- Ebitda 40.52%
(FY 2022)
- Net Worth 25.18%
(FY 2022)
- Total Assets 26.52%
(FY 2022)
About Altius Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.55 M.
The company currently has active open charges totaling ₹3.30 M.
Rajeshkumar Talegaon and Umesh Ramgurwadi serve as directors at the Company.
- CIN/LLPIN
U24232KA2008PTC046233
- Company No.
046233
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Apr 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Belgaum, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Altius Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeshkumar Talegaon  | Director | 29-Apr-2008 | Current |
| Umesh Ramgurwadi | Director | 29-Apr-2008 | Current |
Financial Performance of Altius Pharmaceuticals.
Altius Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 40.19% increase. The company also saw a substantial improvement in profitability, with a 66.42% increase in profit. The company's net worth Soared by an impressive increase of 25.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Altius Pharmaceuticals?
Unlock access to Altius Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 07 Mar 2012 | ₹2.50 M | Open |
Bank Of India Creation Date: 25 Jul 2008 | ₹0.80 M | Open |
How Many Employees Work at Altius Pharmaceuticals?
Altius Pharmaceuticals has a workforce of 47 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Altius Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Altius Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
